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Abstract  
Background: Brain-derived neurotrophic factor (BDNF) is essential for neurogenesis and has been 
implicated in Alzheimer’s disease (AD). However, few studies have investigated together the 
epigenetic transcriptional and translational regulation of this peptide in the brain in relation to AD.  
Objective: To investigate mechanisms underlying for how BDNF is possibly dysregulated in the brain 
in relation to ageing and AD neuropathology. 
Methods: Prefrontal cortex tissues were acquired from the Manchester Brain Bank (N = 67). BDNF 
exon I, and exon IV containing transcripts and total long 3’ transcript gene expression were 
determined by quantitative PCR. Bisulfite pyrosequencing was used to quantify DNA methylation 
within promoters I and IV. Protein concentrations were quantified via an enzyme linked 
immunosorbent assay (ELISA). Donors were previously genotyped for the rs6265 (Val/Met) 
polymorphism. 
Results: BDNF exon IV and total long 3’ isoform gene expression levels negatively associated with 
donor’s age at death (IV: r = -0.291, P = 0.020; total: r = -0.354, P = 0.004). Expression of BDNF exon 
IV containing isoform was significantly higher in Met-carriers of the rs6265 variant, compared to Val-
homozygotes, when accounting for donor ages (F = 6.455, P = 0.014). BDNF total long 3’ transcript  
expression was significantly lower in those with early AD neuropathology, compared to those 
without any neuropathology (P = 0.021). There were no associations between BDNF promoter I and 
IV methylation or protein levels with ages, rs6265 genotype or AD neuropathology status. 
Conclusion: Prefrontal cortex BDNF gene expression is associated with ageing, rs6265 carrier status 
and AD neuropathology in a variant-specific manner. This dysregulation seems to be independent of 
DNA methylation influences at the I and IV promoters.  
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 Introduction 
Brain-derived neurotrophic factor (BDNF) is a neurotrophin that promotes neurogenesis, synaptic 
plasticity and long-term potentiation (LTP) in the CNS [1,2]. BDNF has been implicated in the ‘age-by-
disease hypothesis’, in which BDNF expression is reduced in the ageing brain and a reduction in 
BDNF expression has been associated with multiple neurological disorders [3]. 
Reductions in BDNF have been widely investigated as a mediator of age-associated decline in 
synaptic density and cognitive function [4], with a significant association between BDNF and 
cognitive ageing being observed [5–7]. However, the underlying mechanisms behind age-associated 
BDNF declines are not completely understood. 
The human BDNF gene has a complex structure involving 9 promoters and 11 exons of which only  
the exon IX at the 5’ end contains the  coding sequence [8]. The untranslated 3’ exons, through 
alternative splicing, lead to different transcripts that still contain common coding region at the 3′ 
end. Therefore, through the use of alternative promoters and splicing mechanisms, various different 
BDNF transcripts with alternative 5’ untranslated regions (UTRs) can be generated that all code for 
the same BDNF protein. Finally, two alternative polyadenylated transcription stop sites in exon IX 
can lead to transcripts with either short or long 3′ UTRs. A study has shown that while the short 3′ 
UTR BDNF mRNA variant is restricted to the cell body in hippocampal neurons, the long 3′ UTR 
mRNAs are also observed in dendrites [9]. Together, in the human brain, all exons are expressed, but 
to different degrees in different brain structures  (for review see [10]). It is thought that these 
different promoters allow BDNF to respond to a greater variety of stimuli that further result in the 
generation of different transcripts that are stable in multiple intracellular environments [8]. 
As BDNF promoters mediate differential BDNF isoform expression in various parts of the brain, it is 
thought that changes to their activity could affect cellular and behavioural phenotypes [11]. 
Epigenetic mechanisms, predominantly promoter methylation that generally serves to silence gene 
expression, have been shown to regulate BDNF expression [12]. BDNF promoter IV is one of the 
most widely investigated promoters in the contest of DNA methylation changes associated with 
alterations in BDNF expression: For example McKinney et al. [3] found in the orbital frontal cortex 
that DNA methyation at promoters I, II, and IV were increased in older people and negatively 
correlated with BDNF expression. Keller et al. [13], for example found significant increases in DNA 
methylation at BDNF promoter IV in the Wernicke area from suicide subjects, when compared to 
controls, that correlated with lower mRNA levels for BDNF exon IV containing transcript. In the 
periphery, increased methylation at BDNF promoters I and IV have been found in blood DNA from 
patients with Mild Cognitive Impairment (MCI) compared to controls and increased methylation at 
CpGs in promoter IV predicted conversion from MCI to AD [14]. Further studies in blood DNA have 
shown increased BDNF methylation at promoter I in AD cases compared to controls [15,16] and 
increased peripheral BDNF promoter I and IV in amnestic MCI compared to controls that further 
predicted the conversion from MCI to AD [14]. Interestingly, the conversion from amnestic MCI to 
AD depended upon an interaction of methylation with a non-synonymous single nucleotide 
polymorphism (SNP) in the BDNF gene, rs6265 [17]. However there are some conflicting reports not 
finding increased BDNF methylation in peripheral DNA in AD compared to controls [15,18]. Within 
the CNS, Rao and colleagues [19], studying groups of 10 AD and 10 control prefrontal cortex 
samples, found significant decrease in total BDNF mRNA in the AD brain compared to control brains 
together with increased promoter DNA methylation. A reduction in prefrontal cortex BDNF 
expression in AD has also been found in a study by Buchman et al. [19] on 535 older participants. Li 
et al. [29] found a reduction in temporal cortex and frontal cortex in AD, but specifically in females. 
They further found that rs6265 associated with transcriptional regulation only in the female brains. 
Garzon et al. investigating individual BDNF variants found transcript specific decreases of BDNF in AD 
brains. Few studies have investigated together the epigenetic, genetic, transcriptional and 
translational regulation of this peptide in the brain in relation to AD. 
The aim of this study was to investigate mechanisms underlying the dysregulation of BDNF within 
the AD brains studying human prefrontal cortex tissue for BDNF protein levels, promoter-specific 
expression, promoter DNA methylation specifically at promoters for exons I and IV and the rs6265 
genotype. 
 
Methods 
Study population 
Fresh, frozen tissue was taken from superior frontal gyrus (Brodmann area 8). Samples were 
acquired from donors through the Manchester Brain Bank. Ethical approval was granted from the 
Manchester Brain Bank Committee. Donors were participants of a large prospective cognitive ageing 
cohort known as The University of Manchester Age and Cognitive Performance Research Cohort 
[20,21] and included all those with brain material and available neuropathological data. 
Stratification into Alzheimer’s disease neuropathology groups were based on the National Institute 
on Aging-Alzheimer’s Association guidelines [22]. Briefly, the amyloid beta (Aβ) plaque score (Thal), 
neurofibrillary tangle stage (Braak) and neuritic plaque score (CERAD) were used to create an “ABC” 
score. Four groups were determined: Not, Low, Intermediate and High AD neuropathologic change. 
Those with high levels of Aβ and neuritic plaques with low neurofibrillary tangle score were excluded 
(“ABC“ score: A2-3, B0-1, C0-3), due to potential contributions by other co-morbidities.  
Gene expression analysis 
Brain tissue (~30 mg) was extracted for RNA using TRIsure™ (Bioline, UK), quantified using the 
Nanodrop 2000c (Thermo Scientific, Wilmington, USA) and qualifies using the Agilent Bioanalyser. 
RIN values are given in Supplementary Table 1. The Tetro cDNA synthesis kit (Bioline, UK) was used 
to reverse transcribe total RNA (2 μg), according to the manufacturer’s protocol using random 
hexamers. Relative gene expression was analysed using qPCR with SensiFASTTM SYBR® Lo-ROX kit 
(Bioline), in accordance with the manufacturer’s protocol using primers for BDNF exon I containing 
transcript (F: CAGCATCTGTTGGGGAGACGA; R: GCCACCTTGTCCTCGGATGT), BDNF exon IV containing 
transcript (F:  TGGGAGTTTTGGGGCCGAAG; R: TGGTCATCACTCTTCTCACCTGG), BDNF total long 3’, (F:  
GGACCCTTCAGAGGTGGCTC; R:  GTCGGCTTGAGTGTGGTCCT), ACTB (F: CATCCTCACCCTGAAGTACC; R: 
ATAGCAACGTACATGGCTGG) and GAPDH (F: CCGCATCTTCTTTTGCGTCG; R: 
TGGAATTTGCCATGGGTGGA). qPCR was performed on a Stratagene Mx3000P qPCR system (Agilent) 
in duplicate. Relative gene expression, accounting for primer efficiencies and normalised to GAPDH 
and ACTB, were determined using the geometric averaging method described by Vandesompele and 
colleagues [23]. Those samples with gene expression levels were not detected (Ct ≥40) were 
excluded from analyses. 
Genotyping 
DNA samples were extracted from peripheral blood samples, as described previously [24]. 
Genotyping for the G196A/Val66Met (rs 6265) was performed using the Kompetitive Allele Specific 
PCR (KASP) assay (LGC Ltd) in reaction volumes of 10ul together with 5ng of DNA that was run on a 
Stratagene MX3000P qPCR machine (Agilent). Fluorescence values were read by the MXPro software 
to enable genotype calling. 
Protein quantification 
Brain tissue (~100 mg) were lysed using RIPA buffer (Sigma) supplemented with 1x protease inhibitor 
cocktail and 0.1 M PMSF, as described previously [25]. Quantification of BDNF protein was 
performed using the Human/Mouse BDNF DuoSet ELISA (R&D Systems). Protein levels were 
normalised to total protein levels in the assay (pg/mg of total protein). 
DNA methylation analysis 
Genomic DNA was extracted using the Isolate II Genomic DNA kit (Bioline) and 500 ng bisulfite-
converted using the EpiMark Bisulfite Conversion Kit (New England Biolabs). Primers were used to 
amplify regions of the BDNF promoter I (F: TGAGTGATGATTAAATGGGGATTG; R: BIO-
ACTATTAACTCACATTTAAAAAACCATAAC; S: TGGGGATTGGGGGGA) and promoter IV (F: 
GATTTTGGTAATTCGTGTATTAGAGTGTT; R: BIO-AGATTAAATGGAGTTTTCGTTGAT; S: 
AATGGAGTTTTCGTTGATGGGGTGCA) using MyTaq HS mix PCR reagents (Bioline). The BDNF 
promoter I and promoter IV amplicons contained 5 and 9 CpG sites, respectively. Amplicons were 
processed on the Qiagen Q24 Workstation and sequenced on the Qiagen Q24 pyrosequencer. DNA 
methylation levels across each amplicon were averaged. See Supplemental Figure S1 for locations of 
the regions analysed. 
Statistical analysis 
All analyses were performed using IBM SPSS Statistics (v.25). BDNF isoform expression, protein and 
DNA methylation levels were log10 transformed prior to statistical analysis. Correlations between 
gene expression, DNA methylation and protein levels with donor age were performed using Pearson 
correlation tests. Correlations between gene expression, DNA methylation and protein levels were 
performed using Partial correlation tests, with donor age as a covariate. Differences in gene 
expression, DNA methylation and protein levels between rs6265 variant groups were assessed using 
independent student t-tests. Further, differences between groups while controlling for donor age 
were assessed using a one-way ANCOVA. Differences in gene expression, DNA methylation and 
protein levels between AD neuropathological groups were assessed using one-way ANOVA, as well 
as a one-way ANCOVA to control for age. Results are presented as mean and standard deviation, 
unless otherwise stated. Statistical significance was accepted when P<0.05. 
Results 
Clinical and pathological characteristics of the study population can be found in Table 1. 
Table 1. Clinicopathological characteristics for the donor samples.  
Characteristic Mean (SD) 
Age at death (years) 87.5 (6.1) 
Sex (male/female) 21/46 
Post-mortem delay (hours)a 76.1 (43.7) 
Brain weight (g)b 1207.4 (137.4) 
BDNF rs6265 (N)  
Val/Val 39 (58%) 
Val/Met 25 (37%) 
Met/Met 3 (5%) 
Thal score (N)  
0 (A0) 17 (25%) 
1 (A1) 11 (16%) 
2 (A2) 6 (9%) 
3 (A2) 17 (25%) 
4 (A3) 9 (13%) 
5 (A3) 7 (10%) 
Braak score (N)c  
0 (B0) 4 (6%) 
I (B1) 11 (16%) 
II (B1) 18 (27%) 
III (B2) 13 (19%) 
IV (B2) 12 (18%) 
V (B3) 6 (9%) 
VI (B3) 2 (3%) 
CERAD score (N)  
None (C0) 18 (27%) 
Sparse (C1) 19 (28%) 
Moderate (C2) 18 (27%) 
Frequent (C3) 12 (18%) 
a N = 60 
b N = 43 
c N = 66 
Relationship between BDNF gene expression, DNA methylation and protein levels with age 
The association between BDNF exon I, IV and total long 3’ isoform expression with the age at death 
of donors was investigated (Figure 1). There was a negative association between expression of exon 
IV containing (r = -0.291, P = 0.020; Figure 1B) and total long 3’ (r = -0.354, P = 0.004; Figure 1C) 
BDNF isoforms with age, however, no relationships were evident for BDNF exon I containing isoform 
(r = -0.201, P = 0.149; Figure 1A). 
There were no associations between BDNF protein levels (r = -0.143, P = 0.256) or DNA methylation 
levels (promoter I: r = -0.038, P = 0.761; promoter IV: r = 0.177, P = 0.156) with donor ages. 
Correlations between BDNF gene expression, DNA methylation and protein levels 
The relationships between BDNF gene expression, DNA methylation and protein levels can be seen 
in Table 2. Since donor age significantly correlated with BDNF gene expression, correlations were 
controlled for donor ages throughout.  
Briefly, BDNF exon I isoform expression positively correlated with BDNF exon IV and total long 3’ 
isoform expression. BDNF exon IV expression did not correlate with total long 3’ variant expression. 
Promoter I DNA methylation negatively correlated with BDNF exon I isoform expression levels, 
however this correlation was lost (p=0.08) when account for RIN values (Supplementary Table S2). 
However, there were no associations between promoter IV methylation and BDNF exon IV isoform  
expression levels. Protein levels were not associated with either BNDF exon I, exon IV or total long 
3’UTR RNA expression or DNA methylation levels. 
Table 2. Partial correlation matrix, controlling for donor ages, between BDNF gene expression, 
DNA methylation and protein levels 
 Gene expression  DNA methylation  
 BDNF I BDNF IV BDNF Total  Promoter I Promoter IV Protein 
BDNF I        
BDNF IV 0.586***       
BDNF Total 0.327* -0.233†      
Promoter I -0.282* -0.181 -0.206     
Promoter IV -0.091 0.015 -0.007  0.383   
Protein 0.251† 0.018 0.054  0.074 0.044  
Results displayed are partial correlation coefficient values. † P < 0.10. * P < 0.05. *** P < 0.001. 
Relationship between BDNF gene expression, DNA methylation and protein levels with rs6265 
variant  
The rs6265 variant was in Hardy-Weinberg equilibrium in the study population (X2 = 0.162, P = 
0.687).  
To explore the differences in BDNF gene expression levels with the rs6265 variant, donors were 
stratified into Val-homozygotes and Met-allele carriers. There were no differences in BDNF exon I (t 
= -1.592, P = 0.118) and total long 3’ (t = 0.122, P = 0.904) variant gene expression levels between 
the two groups. However, the Met-allele carriers had significantly higher BDNF exon IV isoform 
expression compared to Val-homozygotes (t = -2.640, P = 0.010) (Figure 2). This difference remained 
after controlling for donor age at death (F = 6.455, P = 0.014) and age AND RIN values (F = 7.229, P = 
0.009). 
There were no differences in BDNF protein levels (t = 0.446, P = 0.657) or DNA methylation levels 
(promoter 1: -0.435, P = 0.665; promoter 4: -0.755, P = 0.453) between rs6265 variants.  
Relationship between BDNF gene expression, DNA methylation and protein levels with 
Alzheimer’s disease pathology 
To investigate the difference in BDNF gene expression with AD pathology, donors were stratified 
based on the NIA-AA “ABC” score, which considers the amyloid plaque, neuritic plaque and 
neurofibrillary tangle scores. These groups were Not, Low, Intermediate and High AD 
neuropathological change. 
Overall, there were differences in BDNF total long 3’ isoform gene expression levels between AD 
pathological groups (F = 3.074, P = 0.035). Specifically, inter-group comparisons revealed a 
significant downregulation of BDNF total long 3’, isoform expression in the Low AD group, compared 
to the Not AD group (P = 0.021) (Figure 3).  
This difference was also apparent when accounting for donor age at death (overall comparison: F = 
3.323, P = 0.026; post-hoc comparison: P = 0.021), however when including age AND RIN values, 
there were no differences (F = 1.909, P = 0.139). 
There were no differences in BDNF exon I (F = 2.766, P = 0.053) or IV (F = 0.405, P = 0.750) isoform 
expression levels between the AD neuropathological groups. Further, there were no differences in 
protein (F = 0.953, P = 0.421) or DNA methylation (promoter 1: F = 1.019, P = 0.391; promoter 4: F = 
1.009, P = 0.396) levels between groups. 
Discussion 
In the prefrontal cortex, BDNF gene expression was associated with donor age, rs6265 carrier status 
and early AD neuropathology in a variant-specific manner. These associations were independent of 
any influences of DNA methylation or protein levels. Thus, we provide further evidence to the 
complex mechanisms dysregulating central BDNF during ageing and neurodegeneration. 
The majority of research investigating age associations of BDNF levels in humans has focussed on 
peripheral measures. Specifically, many reports suggest a gradual reduction in plasma and serum 
concentrations during ageing [6,26–28]. There is, however, limited knowledge of BDNF regulation in 
human brain tissue across ages. We report significant reductions of BDNF exon IV and total long 3’, 
but not exon I, containing isoforms between the ages of 72 and 104 years old. This corroborates 
findings from that of Oh and colleagues, who also reported reductions in total and exon IV- 
containing RNAs in the prefrontal cortex, without any differences in the exon I-containing transcript, 
between ages 16 to 96 years [7]. Because only exon IX contains the coding region, all the different 
exon-containing RNA transcripts will be translated to a single species of BDNF polypeptide. It is 
hypothesised that this sophisticated gene serves to fine-tune a dynamic transcriptional regulation in 
different cell types by different neuronal activities. For example, it has been shown in rodent studies 
that fear conditioning increased both BDNF exon I and IV containing RNA in hippocampus, but only 
exon IV in the CA1 region [29,30] while fear memory extinction elevated BDNF exon I and IV in 
prefrontal cortex [31]. Interestingly, a study on contextual fear conditioning caused a significant 
increase of BDNF exon I in WT hippocampus while the levels of exon IV remained unchanged [32]. 
This highlights that the different exons can be differently regulated. Mechanistically, within BDNF 
exon IV promoter three calcium responsive elements (i.e. CaRE1, 2 and 3) have been identified 
regulating calcium-mediated BDNF IV transcription, while in promoter I there is one CRE in promoter 
I that can be differently regulated by different Ca2+-stimulated protein kinases and other Ca2+-
stimulated intracellular molecules [33].  The calcium hypothesis of aging [34,35], hypothesises a 
dysregulation of intracellular Ca2+ homeostasis is a primary factor contributing to aging-related 
learning and memory impairments in humans and other mammals, that may further relate to AD. 
Perhaps this may reflect differential regulation of BDNF transcritps. Interestingly a NF-kappaB [36] 
site and an E-box [37] have been identified in exon IV promoter that again allow differential 
regulation and may again reflect age-related changes in these regulatory factors in the brain 
[38](Zhang et al). 
We report variant-specific associations with the rs6265 variant. Specifically, Met-carriers had an 
upregulation of BDNF transcripts containing exon IV, but not exon I or total long 3’UTR transcripts, 
compared to Val-homozygotes. The effect of the rs6265 polymorphism on BDNF gene expression is 
largely unknown [39]. A previous study involving over 500 prefrontal cortex donor samples revealed 
no differences of BDNF gene expression between rs6265 genotypes [40]. Despite the superior 
statistical power in this analysis, expression levels of different transcript variants were not reported, 
rather, only total expression. Given our preliminary insight suggesting the influence of the rs6265 
variant may be transcript-specific in BDNF expression, it would be interesting to replicate our 
analysis in this population. 
The reduction in BDNF expression with AD neuropathology is in agreement with other reports 
analysing prefrontal [40], frontal [41], parietal [42] and temporal [41] cortical tissues, as well as the 
hippocampus [41]. Interestingly, our results further suggest the association between expressions 
and neuropathology magnitude may be stage specific. Specifically, those with early AD 
neuropathology having significant BDNF downregulation seem to be particularly affected. Increased 
neuroinflammation is suspected to have a major role in AD progression. The predominant 
hypothesis suggests levels of neuroinflammation peaks early on, possibly reflecting an initial anti-
inflammatory response, followed by a second peak during conversion from MCI to AD, which may 
indicate a pro-inflammatory shift [43,44]. This complex relationship may be related to the microglial 
reaction following the deposition and propagation of amyloid and hyperphosphorylated tau 
pathologies [45]. Numerous studies demonstrate that neuroinflammation in turn affects the 
expression of BDNF within the brain; therefore, reduction of BDNF expression and function may be a 
key mechanism underlying the negative impact of pro-inflammatory cytokines on neuroplasticity 
[46]. 
There are a number of limitations to this study. Variations in postmortem times and RIN values 
(Supplementary Table 1) impacted some of the results such as BDNF promoter I methylation and 
exon I-containing transcript expression, that when we adjusted for, significance was lost. Also, some 
RNA samples were unable to clearly measured for all transcripts from the total 67 subjects (i.e. exon 
I, n=53; exon IV, n=64; long 3’UTR, n=66). A further confounding variable is that the prefrontal cortex 
samples also contain relatively heterogeneous cell populations that were not able to control for. 
Finally, we only investigated specific promoters and transcripts containing exon I, IV and long 3’UTR, 
though it would be interesting to investigate further regions of the BDNF gene and more complete 
coverage of all the different transcripts. 
 
Conclusion 
In conclusion, we report prefrontal cortex BDNF gene expression is associated with ageing, rs6265 
carrier status and AD neuropathology in a variant-specific manner. This dysregulation seems to be 
independent of DNA methylation influences at the I and IV promoters. These results add further 
evidence to the complex regulation of the BDNF gene within the cortex. 
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Figure legends 
 
Figure 1. Associations between donor age at death with A: BDNF I variant, B: BDNF IV variant and C: 
BDNF total mRNA expression. 
 
 
  
 
Figure 2. Difference in BDNF gene expression between rs6265 Val-homozygotes and Met-carriers. 
BDNF I: Val-homozygotes N = 28, Met-carriers N = 25. BDNF IV: Val-homozygotes N = 37, Met-
carriers N = 27. BDNF total: Val-homozygotes N = 38, Met-carriers N = 28 * P < 0.05. 
 
 
  
Figure 3. Difference in BDNF total variant gene expression between AD neuropathology groups. N = 
16 (Not), 14 (Low), 26 (Intermediate), 5 (High). * P < 0.05.  
 
 
 
 
 
Supplementary Figure 1. Schematic of the Human BDNF gene. Untranslated first exons are 
numbered I – VIII and the coding sequence for pro-BDNF is shaded black. Sequences of regions of 
promoters I and IV investigated for DNA methylation [Exon I, chr11:27,722,265-27,722,319; Exon IV, 
chr11:27,701,578-27,701,672 (Hg38)] are shown with CpG residues in bold. 
 
Supplemental Table 1. Sample details. 
Patient
_Code 
Age_at_
death 
Gende
r 
Brain_
Weight PMD 
Primary_Pathology_Diagnosis_D
escription RIN_Value 
22708 91 F 1216.00 133.0 Age changes only 3.20 
11052 94 F 946.00 111.0 Age changes only 5.30 
10540 98 F 1029.00 84.0 Possible AD 6.10 
11383 100 F 1058.00 61.5 CAA 4.60 
21337 86 F 1334.00 96.0 AD 6.10 
12284 96 F - 154.0 Moderate AD pathology 2.30 
11060 83 F 1108.00 94.0 Mild AD changes in temporal lobe 2.30 
11299 89 M 1070.00 36.0 
Age-related tau astrogliopathy 
with hippocampal sclerosis and 
secondary TDP-43 4.90 
22625 91 M 1157.00 93.0 Age changes only 4.00 
10192 97 M 1252.00 120.5 
Argyrophilic Grain Disease with 
v.mild AD-like tau 2.60 
20274 94 F 1166.00 86.0 Early/Incipient AD 2.80 
11618 79 F - 116.0 Argyrophilic Grain Disease 3.40 
10502 81 F 1160.00 113.5 Probable AD 5.30 
10544 89 F 1450.00 144.0 CAA (?)moderate SVD 2.90 
11971 81 F 1363.00 44.0 Early/incipient AD 4.50 
23096 76 F 1204.00 47.0 Mild AD changes in temporal lobe 2.30 
22091 82 F 1020.00 61.0 Age changes only 2.70 
12762 90 F 1217.00 103.0 Age changes only 4.40 
22105 89 M - 128.0 Incipient AD 5.60 
12504 90 M - 156.0 Age changes only #NULL! 
10640 104 F 1289.00 78.0 AD 3.10 
22194 88 F 1129.00 4.0 Early limbic predominant DLB 5.90 
22867 93 F 1133.00 70.5 Probable AD 2.50 
21297 85 M - 187.5 Mild CAA 4.20 
20088 90 F - 41.5 Age changes only 2.30 
21179 86 M 1100.00 26.0 AD 2.30 
11845 89 F - 36.0 CVD 2.30 
21683 90 F 1050.00 39.0 Age changes only 6.30 
22340 76 F 1359.00 129.5 Age changes only 6.50 
12698 87 F - 39.0 Age changes only 5.80 
11240 89 M - 27.0 Age changes only 3.30 
11379 80 F 1000.00 81.0 Probable AD 4.60 
20845 95 F 1116.00 88.0 Possible AD 3.40 
22110 85 M - 12.0 Age changes only 5.00 
21493 91 M - - Moderate SVD 3.30 
21092 87 F 1152.00 24.0 Age changes only 2.50 
11662 81 F 1250.00 - Incipient AD 2.30 
10719 72 F 1230.00 - Incipient AD 2.60 
20429 92 M - 24.0 Moderate CVD 3.40 
11802 89 F - 134.0 Mild AD pathology 5.10 
11176 82 F 1174.00 46.0 Mild DLB 4.50 
11427 78 M - 144.0 Age changes only 5.70 
11550 94 M 1550.00 42.0 CAA? 6.80 
20428 82 F - 96.0 Probable AD 3.20 
11341 92 M 1270.00 48.0 Early/incipient AD 2.90 
22691 79 F 1290.00 - Incipient AD 2.30 
22083 87 M - 120.0 Mild AD 2.45 
20402 89 F - 72.0 AD 4.50 
20382 78 F - - Probable AD 2.50 
11508 94 F 1150.00 - Age changes only 3.40 
10004 86 M - 18.0 DLB 2.70 
12755 89 F 1351.00 56.0 Moderate AD pathology 2.60 
22272 93 M 1348.00 39.0 Mild transitional DLB 2.30 
22738 88 F - 72.0 Mild CVD 2.70 
12022 82 F 1210.00 120.0 Mild AD/PD path. 2.20 
10664 90 M 1134.00 114.5 Corticobasal degeneration 4.80 
12033 91 M 1520.00 43.5 Mild SVD 4.00 
10772 87 F 1019.00 60.0 AD 3.10 
20935 92 F - 37.0 Age changes only 2.40 
10132 81 F 1210.00 41.0 Age changes only 3.50 
12221 87 M 1410.00 80.0 CVD 2.40 
21664 90 F - 6.0 Possible AD 2.40 
10118 87 F 1178.00 87.0 Mild AD path. in temporal lobe 4.70 
11426 88 F - 72.0 AD 2.60 
12413 80 M 1240.00 - Incipient AD 2.20 
11322 87 F 1305.00 120.0 PD 6.50 
10954 85 F - 12.0 Mild CAA 2.50 
Alzheimers Disease, AD; Parkinsons Disease, PD; cerebral amyloid angiopathy, CAA; cerebrovascular 
disease, CVD;  
Supplemental Table 2. Pearson correlations between BDNF gene expression, methylation and 
protein with RIN and PMD times 
 
 
 
Correlations 
 
LgBDNF_Transcri
pt1_Exp_New 
LgBDNF_Transcri
pt4_Exp_New 
LgBDNF_Total_Ex
p_New 
LgMeth_PromI_Av
g 
LgBDNF_Trans
cript1_Exp_Ne
w 
Pearson Correlation 1 .608** .371** -.268 
Sig. (2-tailed)  .000 .006 .054 
N 53 53 53 52 
LgBDNF_Trans
cript4_Exp_Ne
w 
Pearson Correlation .608** 1 -.106 -.162 
Sig. (2-tailed) .000  .406 .205 
N 53 64 64 63 
LgBDNF_Total_
Exp_New 
Pearson Correlation .371** -.106 1 -.179 
Sig. (2-tailed) .006 .406  .153 
N 53 64 66 65 
LgMeth_PromI_
Avg 
Pearson Correlation -.268 -.162 -.179 1 
Sig. (2-tailed) .054 .205 .153  
N 52 63 65 66 
LgMeth_PromI
V_Avg 
Pearson Correlation -.124 -.038 -.069 .102 
Sig. (2-tailed) .378 .768 .585 .418 
N 53 64 65 65 
LgBDNFprotein Pearson Correlation .272 .058 .101 .078 
Sig. (2-tailed) .051 .652 .427 .539 
N 52 62 64 64 
RNA RIN Value Pearson Correlation -.058 .244 -.475** .026 
Sig. (2-tailed) .678 .052 .000 .836 
N 53 64 66 65 
Postmortum 
delay (hours) 
Pearson Correlation .037 -.066 -.043 -.144 
Sig. (2-tailed) .799 .626 .746 .277 
N 49 57 59 59 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
 
Supplemental Table 3. Partial correlation matrix, controlling for donor ages and RIN values, 
between BDNF gene expression, DNA methylation and protein levels 
 
Correlations 
Control Variables 
LgBDNF_Transcri
pt1_Exp_New 
LgBDNF_Transcri
pt4_Exp_New 
RNA RIN Value & Age at death LgBDNF_Transcript1_Exp_New Correlation 1.000 .596 
Significance (2-tailed) . .000 
df 0 47 
LgBDNF_Transcript4_Exp_New Correlation .596 1.000 
Significance (2-tailed) .000 . 
df 47 0 
LgBDNF_Total_Exp_New Correlation .301 .149 
Significance (2-tailed) .035 .306 
df 47 47 
LgMeth_PromI_Avg Correlation -.253 -.137 
Significance (2-tailed) .080 .347 
df 47 47 
LgMeth_PromIV_Avg Correlation -.090 .034 
Significance (2-tailed) .539 .818 
df 47 47 
LgBDNFprotein Correlation .266 .039 
Significance (2-tailed) .065 .790 
df 47 47 
 
 
 
